PRESS RELEASES
. . . . . .
April 5, 2022
Respira Therapeutics Announces First Patient Dosed in Phase 2b VIPAH-PRN 2b Trial of RT234 in Patients with Pulmonary Arterial Hypertension (PAH)
Phase 2 clinical trials of our leading pipeline candidate are underway
. . . . . .
Respira’s lead drug-device product candidate, RT234-PAH, is a first-in-class inhaled therapy intended for as-needed (PRN) use by patients experiencing symptoms. This contrasts with all other current PAH treatments, which are taken according to a chronic treatment regimen.